With its FDA-approved neurostimulator implant aimed at helping patients recover from stroke, MicroTransponder has raised $65 ...

An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...

Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

The National Institutes of Health (NIH) is continuing its grant-canceling spree, allegedly targeting dozens of research ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The AI-focused company is handing over $200 million as an upfront payment, as well as ...

Bindman, a professor at the University of California-San Francisco medical school, has spent well over a decade researching ...